… In the COMPASS (Cardiovascular Outcomes for … coronary artery disease (CAD) or peripheral
artery disease (PAD), the combination of 2.5 mg rivaroxaban twice daily and 100 mg aspirin …

… stable coronary artery disease or peripheral artery disease, the combination of rivaroxaban
(2.5 mg twice daily) and aspirin … with stable atherosclerotic vascular disease, rivaroxaban 2.5 …

… rivaroxaban and aspirin compared with aspirin and of rivaroxaban alone compared with
aspirin … by treatment with proton pump inhibitor (not randomized to proton pump inhibitor, …

… For patients enrolled in LTOLE, we also report treatments (non-antithrombotic and
antithrombotic) received in the interval between the final rivaroxaban/aspirin visit and LTOLE …

… stable” coronary artery disease or PAD remain at a substantially increased long-term risk of
cardiovascular events… termed to have “stable” coronary artery disease are now referred to as …

… and PAD patients at risk of cardiovascular events with rivaroxaban plus aspirin DPI improves
health outcomes and seems overall to be cost-effective compared with aspirin ATP, and …

… combination therapy in secondary prevention of major adverse cardiovascular events in …
patients with stable coronary artery disease and peripheral artery diseases were recruited …

… disease. Using only single-antiplatelet therapy for secondary prevention in patients … stable
coronary artery disease (SCAD) and/or peripheral artery disease (PAD) has a significant risk …

… In conclusion, low-dose rivaroxaban plus aspirin versus aspirin alone is less likely to be
cost-effective in secondary prevention for patients with stable cardiovascular diseases. …

… incidence of total cardiovascular and/or bleeding events than combination anticoagulant
and antiplatelet therapy in patients with atrial fibrillation and stable coronary artery disease? …